A Phase I Open Label Study of E7974 Administered on Day 1 of a 21-Day Cycle In Patients With Advanced Solid Tumors.

Trial Profile

A Phase I Open Label Study of E7974 Administered on Day 1 of a 21-Day Cycle In Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Sep 2009

At a glance

  • Drugs E 7974 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Aug 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
    • 11 Aug 2009 Status changed from active, no longer recruiting to completed, as reported in ClinicalTrials.gov record.
    • 12 Dec 2008 Status changed from recruiting to active, no longer recruiting, as reported in ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top